Kasumi Haruta's questions to Takeda Pharmaceutical Co Ltd (TAK) leadership • Q1 2025
Question
Kasumi Haruta from UBS inquired how the R&D organization plans to improve productivity with a reduced headcount after restructuring, and asked if the 2030-2032 timeline for ENTYVIO biosimilar entry remains firm given competitor progress.
Answer
R&D President Andy Plump explained that productivity gains will come from pipeline prioritization and leveraging efficiencies from data, digital, and technology. President and CEO Christophe Weber confirmed no change to the 2030-2032 U.S. biosimilar entry assumption for ENTYVIO, noting that the ENTYVIO Pen does not extend this patent protection.